Two Directors Bought Shares of Everest Group (EG) Cheaper Than the CEO Did 6 Months Ago: Will Buying Now Culminate in Profits?

NYSE: EG — $314.52 (+1.73%) as of Oct-31-2025, 4:10 PM ET
Subtitle: You may never climb Everest, but you can still try for altitude.

Everest in One Breath 🌍🧾

Everest Group, Ltd. (formerly Everest Re) is a global underwriting leader selling reinsurance and insurance across property, casualty, and specialty lines. Think catastrophe (cat) reinsurance (hurricanes, quakes), marine/aviation, mortgage, engineering, credit & surety, agribusiness—the works. Founded in 1973, headquartered in Hamilton, Bermuda, renamed in 2023. Two operating engines: Reinsurance and Insurance.

Trigger #1: Fresh Insider Buys 🧭💰

Recent purchases (10/29/2025) by two directors—at lower prices than the CEO’s buy in June:

• William F. Galtney Jr. (Director): 11,385 shares @ $307.38 → +33% to 45,491 (≈ $3.50M).

• Allan Levine (Director): 3,100 shares @ $306.08 → +294% to 4,153 (≈ $948.8K).

• Jim Williamson (CEO, 6/11/2025): 1,000 shares @ $337.97 (≈ $338K).

👀 Read: directors leaning in below the CEO’s entry six months ago = a confidence nudge.

Trigger #2: The Pros Are Piled In 🧺🏦

• Insiders hold: ~1.46%

• Institutions hold: ~99% of shares and 100%+ of float (mechanics of lending/shorting can push this >100%).

• 1,000+ institutions on the roster.
  Top holders (6/30/2025 snapshots): Vanguard, BlackRock, State Street, Norges, Wellington, AQR, Geode, Vulcan Value, etc.
  Short interest: ~1.96% of float → not many bears.

For Everest Group (EG)'s Institutional Ownership breakdown, 🔍 see here.

Q3 2025: A Reset in Motion 🔧📉➡️📈

Earnings (reported Oct 27, 2025):

• Net income: $255M ($6.09/share) vs. $509M prior-year quarter.

• Net operating income: $316M ($7.54/share) vs. $630M prior-year quarter.

• Gross Written Premium: $4.4B (Group −1.2% YoY; Reinsurance −1.7%; Insurance +2.7%).

• Combined ratios: Group 103.4%; Reinsurance 87.0%; Insurance 138.1% (U.S. casualty reserve strengthening hits hard).

• Prior-year reserve development: ~$478M unfavorable, adding 12.4 pts to the Group combined ratio.

• Cat losses: $50M (much lower vs. $279M in Q3’24).

• Net investment income: $540M vs. $496M.

• Operating cash flow: $1.5B vs. $1.7B.

Strategic moves:

1. Adverse Development Cover (ADC): $1.2B across two layers (Everest co-participates $100M each). Designed to ring-fence prior-year North America Insurance & Other liability reserves (AY 2024 & prior) and reduce volatility.

2. Sale of renewal rights for its Retail Commercial Insurance business to AIG (≈ $2B GWP). Frees capital, simplifies mix; expect a $250–$350M pre-tax non-operating charge spread over 2025–2026.

Translation: This is a portfolio and balance-sheet scrub. The near-term P&L looks messy; the aim is a cleaner, higher-return Everest centered on Reinsurance and Wholesale & Specialty Insurance.

 👉 Want the full picture? Dive into Everest Group (EG)'s financials here.

What It Might Mean for Shareholders 🧭

• Quality over breadth: Exiting lower-return retail lines + ADC should dampen reserve tail risk, even if it dents reported results near-term.

• Capital deployment flexibility: Potential room for buybacks, selective hiring, tech/data investments, and underwriting into strong cat pricing.

• Reinsurance tailwinds: Hard market in cat reinsurance remains the star—attractive risk-adjusted returns if discipline holds and losses don’t spike.

Valuation Snapshot 🧮

• Market Cap: ~$14.7B

• Trailing P/E: 18.3x | Forward P/E: ~5.5x (cheap if estimates hold)

• Price/Book: ~0.98x

• EV/Sales: ~0.94x

Analyst scaffolding: revenue modestly down next 3 yrs; margin expansion forecast (Net Op. margin from well under 10% → closer to 20% in 3 yrs); EPS path to ~$70.6 by ~2028 with buybacks reducing share count ~2.4%/yr. To hit certain price targets, the stock could be valued at ~5x 2028E EPS—below the current U.S. Insurance industry P/E ~14x. If Everest executes, multiple expansion is optionality.

Why Bulls Have a Case 🐂✨

• Hard cat reinsurance market: disciplined terms/pricing, high barriers; Everest can lean into best-priced risk.

• Portfolio pruning: less problematic U.S. casualty, more specialty/international, better earned mix over time.

• Tech & analytics: underwriting selection keeps compounding; expense ratio should improve with scale.

• Capital strength: ADC + renewal rights sale free up capital and spotlight the core moats.

The “But” List (Know Thy Risks) 🧊⚠️

• Climate + cat clustering: more frequent/severe events = earnings volatility; one bad season can swamp a quarter.

• Competition & alternative capital: cat bonds/ILS can compress spreads; large accounts already seeing rate pressure.

• Insurance expense ratio: build-out costs still heavy; if growth lags, margins drag longer.

• Reserve risk: ADC helps, but if casualty severity trends worsen, more reserve action could be needed.

• Cycle timing: reinsurance is cyclical; if pricing normalizes faster than expected, upside narrows.

💡💡💡 Curious about another deep oil exploration play?
Check our takes on UnitedHealth Group or even Oscar Health.

So… Buy the Dip or Pack Oxygen? 🏔️🪙

Insiders are buying below the CEO’s June print, institutions are deeply invested, and management is actively de-risking the book. The tug-of-war is between near-term fog (reserve charges, business remix) and medium-term clarity (leaner mix, hard-market underwriting, capital flexibility). For valuation-aware investors who can stomach insurance cyclicality and cat volatility, risk/reward is turning attractive. Position size accordingly; add more on dislocations.

(We’re not your advisor; just your fun-loving sherpa.)

Quick Take / TL;DR ⚡

• Catalyst: Two directors bought shares around $306–$307, below the CEO’s $338 buy in June.

• Institutions: Own essentially all the float; short interest ~2%.

• Q3 Reset: ADC ($1.2B), selling retail renewal rights to AIG; near-term pain, long-term focus.

• Valuation: Forward P/E ~5–7x; P/B ~1x.

• Call: Constructive with caveats—consider staged entries; respect the cat cycle.

FAQ 🧠

Q: Why are directors buying now?
A: Likely signaling confidence after the ADC and renewal-rights sale—i.e., the heavy lifting to stabilize reserves and sharpen the business mix is underway.

Q: Isn’t catastrophe reinsurance too risky?
A: It’s volatile, yes—but pricing/terms are attractive in hard markets. The trick is underwriting discipline, retro cover, and portfolio construction. Expect lumpy quarters.

Q: What does the ADC actually do?
A: It caps a chunk of prior-year reserve uncertainty. You still pay for it (consideration), but it reduces tail risk and future P&L shocks from those specific books.

Q: Why sell renewal rights instead of the whole business?
A: It’s a faster, cleaner way to exit low-return lines, free capital, and avoid operational drag—while letting clients follow brokers to the new carrier (AIG).

Q: Is EG “cheap for a reason”?
A: Possibly short-term uncertainty (reserves, expense ratio, mix shift). If execution lands, the “reason” fades and multiples can re-rate.

🧾⚠️📢 Fun/ny (but real) Disclaimer: 🧾⚠️📢

🧫 Disclosure: We climb numbers, not mountains. This is education and entertainment, not investment advice. 

Always DYOR, mind your altitude sickness, size positions to your risk tolerance, and remember: even sherpas check the weather. Also, hold the FOMO, and don’t invest what you can’t afford to lose.

Keep your humor cells alive. 🧬  We laugh, we analyze, we meme. We sell jokes and opinions — and yes, we’re billing your sense of humor. 😄 We’re not financial advisors. We’re FUNancial advisors. 🎪💸 

Invest at your own risk. 💸💧 

🧭 Want More Like This?

• 🕵️ Insider Purchases Center
• 📣 Follow the Pundits Hub
• 📈 Young Guns & Turnaround Stocks — Track More Growth (and Growing-Pain) Plays
• 😆 Stock Market Humor & Serious-ish Plays
• 🌍 See the world differently and check out more international market picks and fun takes. Explore International Investment Opportunities and value plays 💸 Cheap Stocks with (Maybe) Big Upside
• 🧟 Corporate Resurrection Series — Our special series on companies rising from the financial grave. 🎯 The “Turnaround or Toast” Series (If it still exists. We’re not sure. Ask the intern.)
• 📈 Biotech Bets & Innovation Radar (Problem is we can't detect the Radar)

😂 Laugh, Learn, Invest: funanc1al.com | Funanc1al: Where Even Finance Meets Funny